记录分析分析阿尔茨海默氏症的大脑。(S28.005)

文摘

目的:使用现有的微阵列数据来识别基因差异表达的广告与non-AD大脑。背景:尽管最近的成功加载GWAS研究中,大部分的遗传负荷仍然无法解释。我们假设评估大脑基因表达提供了一个额外的途径识别小说负载基因和通路可能是潜在的药物靶点。我们之前进行了基因表达GWAS的mRNA水平评估~ 24000记录在两个脑区(颞叶皮层和小脑)200 ~ 200年的广告主题和~主题与其他疾病我们现在进行记录分析分析比较广告和non-AD科目之间的基因表达水平在这两个大脑区域和途径进行分析这些数据。此外,我们正在收集全基因组CpG甲基化数据(methylome)的一个子集这些主题为未来的评估。设计/方法:基因表达水平的Illumina公司HT-12 V4 BeadChip数组使用全基因组表达DASL HT化验和适当的数据质量控制实施。记录分析使用线性回归分析进行了R与适当的协变量。基因通路分析分别使用两个大脑区域MetaCore执行。结果:QC ~ 17000后基因表达强劲措施发现在每一个大脑区域。记录分析分析确定了743目标在小脑和2839年目标在颞叶皮层(un-corrected p值< 0.01),选择路径分析。 In the temporal cortex several significant pathways and GO Processes were identified including but not limited to oxidative phosphorylation and lipid metabolism. CONCLUSIONS: Transcript profiling and pathway analysis of brain gene expression data has identified several interesting targets for further exploration of molecular pathways involved in AD. The addition of methylome data will further enhance our understanding of the role of gene expression and control in this disease. Study Supported by: R01 AG032990, P50 AG016574, Mayo Clinic Center for Individualized Medicine Epigenomics Grant.

披露:艾伦博士没有披露。联赛博士没有披露。沃尔什博士没有披露。芝罘区博士没有披露。Baheti博士没有披露。邹博士没有披露。茶博士没有披露。Younkin博士没有披露。克鲁克博士没有披露。Pankratz说道已收到博士研究雅培公司的支持,公司Carrasquillo博士没有披露。 Dr. Nair has nothing to disclose. Dr. Middha has nothing to disclose. Dr. Maharjan has nothing to disclose. Dr. Nguyen has nothing to disclose. Dr. Ma has nothing to disclose. Dr. Malphrus has nothing to disclose. Dr. Lincoln has nothing to disclose. Dr. Bisceglio has nothing to disclose. Dr. Kolbert has nothing to disclose. Dr. Jen has nothing to disclose. Dr. Petersen has received personal compensation for activities with Pfizer, Inc., and Janssen Alzheimer's Immunotherapy. Dr. Petersen has received royalty payments from Oxford University Press. Dr. Graff-Radford has received personal compensation for activities with Codman as a member of a scientific advisory board. Dr. Graff-Radford has received personal compensation in an editorial capacity for The Neurologist. Dr. Graff-Radford has received research support from Janssen, Pfizer Inc., Medivation, Forest Laboratories Inc., and Allon. Dr. Dickson has received personal compensation for activities with Neotope, Inc. as a consultant. Dr. Younkin has nothing to disclose. Dr. Asmann has nothing to disclose. Dr. Taner has nothing to disclose.